glp-1 specialist indianapolis in GLP1-S (Starting at $25) Drug companies pay Indiana doctors

Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]

1,3,4 Tirzepatide 15mg Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity

The STEP 1 trial (N=1,961) published in the New England Journal of Medicine in 2021 (DOI: 10.1056/NEJMoa2032183) demonstrated 14.9% mean body weight reduction with semaglutide 2.4mg weekly versus 2.4% with placebo over 68 weeks

Referncias ORGANIZAO MUNDIAL DA SADE (OMS)